Coloplast Statistics
Total Valuation
Coloplast has a market cap or net worth of 14.93 billion. The enterprise value is 18.63 billion.
| Market Cap | 14.93B |
| Enterprise Value | 18.63B |
Important Dates
The next confirmed earnings date is Tuesday, May 12, 2026.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | Dec 8, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.17% |
| Shares Change (QoQ) | -0.18% |
| Owned by Insiders (%) | 5.33% |
| Owned by Institutions (%) | 21.12% |
| Float | 143.38M |
Valuation Ratios
The trailing PE ratio is 23.81 and the forward PE ratio is 16.67.
| PE Ratio | 23.81 |
| Forward PE | 16.67 |
| PS Ratio | 3.41 |
| PB Ratio | 6.88 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 17.36 |
| P/OCF Ratio | 13.82 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.62, with an EV/FCF ratio of 21.66.
| EV / Earnings | 29.71 |
| EV / Sales | 4.33 |
| EV / EBITDA | 13.62 |
| EV / EBIT | 15.78 |
| EV / FCF | 21.66 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 1.82.
| Current Ratio | 1.30 |
| Quick Ratio | 0.76 |
| Debt / Equity | 1.82 |
| Debt / EBITDA | 2.83 |
| Debt / FCF | 4.59 |
| Interest Coverage | 10.74 |
Financial Efficiency
Return on equity (ROE) is 27.26% and return on invested capital (ROIC) is 13.08%.
| Return on Equity (ROE) | 27.26% |
| Return on Assets (ROA) | 9.85% |
| Return on Invested Capital (ROIC) | 13.08% |
| Return on Capital Employed (ROCE) | 18.74% |
| Weighted Average Cost of Capital (WACC) | 6.15% |
| Revenue Per Employee | 258,186 |
| Profits Per Employee | 36,926 |
| Employee Count | 16,983 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 2.38 |
Taxes
In the past 12 months, Coloplast has paid 344.29 million in taxes.
| Income Tax | 344.29M |
| Effective Tax Rate | 35.44% |
Stock Price Statistics
The stock price has decreased by -35.36% in the last 52 weeks. The beta is 0.55, so Coloplast's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -35.36% |
| 50-Day Moving Average | 7.65 |
| 200-Day Moving Average | 8.83 |
| Relative Strength Index (RSI) | 34.14 |
| Average Volume (20 Days) | 829,260 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Coloplast had revenue of 4.38 billion and earned 627.11 million in profits. Earnings per share was 2.78.
| Revenue | 4.38B |
| Gross Profit | 2.98B |
| Operating Income | 1.20B |
| Pretax Income | 971.41M |
| Net Income | 627.11M |
| EBITDA | 1.35B |
| EBIT | 1.20B |
| Earnings Per Share (EPS) | 2.78 |
Balance Sheet
The company has 176.86 million in cash and 3.95 billion in debt, with a net cash position of -3.77 billion.
| Cash & Cash Equivalents | 176.86M |
| Total Debt | 3.95B |
| Net Cash | -3.77B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.17B |
| Book Value Per Share | 9.64 |
| Working Capital | 372.59M |
Cash Flow
In the last 12 months, operating cash flow was 1.08 billion and capital expenditures -220.10 million, giving a free cash flow of 860.10 million.
| Operating Cash Flow | 1.08B |
| Capital Expenditures | -220.10M |
| Depreciation & Amortization | 142.62M |
| Net Borrowing | 18.02M |
| Free Cash Flow | 860.10M |
| FCF Per Share | n/a |
Margins
Gross margin is 67.87%, with operating and profit margins of 27.46% and 14.30%.
| Gross Margin | 67.87% |
| Operating Margin | 27.46% |
| Pretax Margin | 22.15% |
| Profit Margin | 14.30% |
| EBITDA Margin | 30.78% |
| EBIT Margin | 27.46% |
| FCF Margin | 19.62% |
Dividends & Yields
This stock pays an annual dividend of 0.22, which amounts to a dividend yield of 3.20%.
| Dividend Per Share | 0.22 |
| Dividend Yield | 3.20% |
| Dividend Growth (YoY) | 7.27% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 129.96% |
| Buyback Yield | -0.17% |
| Shareholder Yield | 3.04% |
| Earnings Yield | 4.20% |
| FCF Yield | 5.76% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Coloplast has an Altman Z-Score of 4.11 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.11 |
| Piotroski F-Score | 7 |